Zanamivir - Generic Drug Details

What are the generic sources for zanamivir and what is the scope of freedom to operate?

Zanamivir is the generic ingredient in one branded drug marketed by Glaxosmithkline and is included in one NDA. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for zanamivir

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	84
Clinical Trials:	34
What excipients (inactive ingredients) are in zanamivir?	zanamivir excipients list
DailyMed Link:	zanamivir at DailyMed

Recent Clinical Trials for zanamivir

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Oxford	Phase 2
Hospital Infantil de Niño Jesús de Barranquilla (HINJ)	Early Phase 1
Universidad Bosque	Early Phase 1

See all zanamivir clinical trials

Pharmacology for zanamivir

Drug Class	Neuraminidase Inhibitor
Mechanism of Action	Neuraminidase Inhibitors

Medical Subject Heading (MeSH) Categories for zanamivir

Antiviral Agents

Enzyme Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for zanamivir

J05AH	Neuraminidase inhibitors
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

US Patents and Regulatory Information for zanamivir

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	RELENZA	zanamivir	POWDER;INHALATION	021036-001	Jul 26, 1999		RX	Yes	Yes

Expired US Patents for zanamivir

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Glaxosmithkline	RELENZA	zanamivir	POWDER;INHALATION	021036-001	Jul 26, 1999	4,627,432
Glaxosmithkline	RELENZA	zanamivir	POWDER;INHALATION	021036-001	Jul 26, 1999	5,648,379
Glaxosmithkline	RELENZA	zanamivir	POWDER;INHALATION	021036-001	Jul 26, 1999	D379506
Glaxosmithkline	RELENZA	zanamivir	POWDER;INHALATION	021036-001	Jul 26, 1999	4,778,054
Glaxosmithkline	RELENZA	zanamivir	POWDER;INHALATION	021036-001	Jul 26, 1999	5,360,817
Glaxosmithkline	RELENZA	zanamivir	POWDER;INHALATION	021036-001	Jul 26, 1999	5,035,237

EU/EMA Drug Approvals for zanamivir

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
GlaxoSmithKline Trading Services Limited	Dectova	Zanamivir	EMEA/H/C/004102Dectova is indicated for the treatment of complicated and potentially life-threatening influenza A or B virus infection in adult and paediatric patients (aged ≥6 months) when:The patient’s influenza virus is known or suspected to be resistant to anti-influenza medicinal products other than zanamivir, and/orOther anti-viral medicinal products for treatment of influenza, including inhaled zanamivir, are not suitable for the individual patient.Dectova should be used in accordance with official guidance.	Authorised	no	no	no	2019-04-26

Market Dynamics and Financial Trajectory for Zanamivir

Last updated: February 19, 2026

Zanamivir is an antiviral drug approved for the treatment and prevention of influenza. This analysis covers its market landscape, competitive positioning, revenue trends, pricing strategies, regulatory environment, and future growth prospects.

What Is Zanamivir's Market Position?

Zanamivir, marketed as Relenza by GlaxoSmithKline (GSK), is a neuraminidase inhibitor approved primarily for influenza A and B. It occupies a niche within antiviral therapies alongside oseltamivir (Tamiflu). The drug's innovative delivery method involves inhalation via Diskhaler, which limits its use to patients with suitable inhalation capability.

Key Market Share and Competitors

Brand	Active Ingredient	Market Share (2022)	Administration Method	Approval Year	Price Range (per course)
Relenza	Zanamivir	10%	Inhalation	1999	$120–$150
Tamiflu	Oseltamivir	55%	Oral capsule	1999	$70–$100
Peramivir	Peramivir	25%	IV infusion	2014	$300–$500
Baloxavir	Baloxavir marboxil	10%	Oral, single-dose	2018	$150–$200

Zanamivir’s market share has declined from its peak in the early 2000s and faces competition from orally administered antivirals that offer higher convenience.

How Has the Revenue Trajectory Evolved?

GSK’s annual sales of Relenza have decreased over the past decade. In 2012, global sales exceeded $200 million; recent estimates suggest revenue below $50 million globally, primarily driven by demand in specific regions and limited pandemic usage.

Revenue Trends:

• 2012: $200 million (approximate)
• 2016: $80 million
• 2020: $60 million
• 2022: $45 million

The decline results from OTC preferences, competition, and inhalation limitations. Influenza outbreaks influence immediate sales but do not sustain long-term revenue growth.

Pandemic Impact

During the 2009 H1N1 influenza pandemic, demand surged temporarily, leading to increased stockpiling in certain regions. GSK supplies stockpiles to government agencies periodically, impacting short-term revenue fluctuations but not establishing sustained growth.

Price Strategy and Accessibility

Pricing varies by region and healthcare coverage. GSK sets a list price around $120–$150 per treatment course, often reimbursed in developed markets. Limited reimbursement and competition from generics lower utilization in some territories.

Patent and Generic Status

• Patent expiry anticipated around 2024–2025.
• No generic versions yet available but expected soon due to patent expiration.

Regulatory Environment and Approvals

Zanamivir is approved by the FDA (1999) andEMA (2000) for influenza treatment and prophylaxis. No significant regulatory barriers are anticipated; however, new formulations or delivery methods would require additional approval processes.

Future Growth Prospects

Potential growth areas include:

• New formulations: Powder inhalers or nasal sprays to improve administration.
• Use in pandemic preparedness: As stockpiling persists, sales may stabilize during outbreak periods.
• Combination therapies: Development of combo treatments with other antiviral agents.

However, innovation has been limited; the drug faces stiff competition from newer oral antivirals.

Key Market Drivers

• Seasonal influenza outbreaks.
• Pandemic preparedness strategies.
• WHO and government stockpiling policies.
• Patent expiration leading to generics.

Challenges to Market Expansion

• Inhalation device limitations, especially among pediatric and elderly populations.
• Competition from oral antivirals that don't require inhalation.
• Limited evidence of superior efficacy over competitors.
• Price sensitivity and reimbursement challenges.

Summary of Financial Outlook

Scenario	Revenue Potential	Key Factors
Baseline	Declining, below $50 million annually	Competitive pressures, device limitations
Growth through new formulations	Up to $100 million within 5 years	Successful development of alternative delivery methods
Pandemic stockpile use	Temporary surge, potential renewal	Global influenza activity, stockpiling policies

Key Takeaways

• Zanamivir's global sales have declined steadily since 2012.
• The market is saturated with oral antivirals, limiting future growth.
• Patent expiration is imminent, prompting regulatory and commercial preparations for generic entry.
• Growth opportunities lie mainly in new formulations and pandemic-related demand.
• Pricing remains consistent in developed markets, but reimbursement constraints affect penetration elsewhere.

FAQs

Q1: What factors could revitalize zanamivir’s market?
Development of user-friendly inhalation devices or alternative formulations could expand its user base.

Q2: How does patent expiry impact zanamivir’s revenue?
Patent expiry opens the market to generics, likely reducing GSK’s pricing power and sales volume.

Q3: Are there new competitors emerging in the influenza antiviral space?
Yes. Baloxavir marboxil entered the market in 2018, offering a single-dose oral option.

Q4: How significant is pandemic preparedness for zanamivir’s future?
Pandemic preparedness remains a critical driver; stockpiling policies keep demand alive temporarily.

Q5: What regulatory challenges could influence commercialization?
Approval of new formulations or delivery methods would require additional clinical trials and regulatory clearance.

---

References

1. GSK. (2022). Relenza (zanamivir) Prescribing Information.
2. U.S. Food & Drug Administration. (1999). ZANAMIVIR (RELENZA) approval documentation.
3. European Medicines Agency. (2000). Relenza (zanamivir) Summary of Product Characteristics.
4. IQVIA. (2022). Global Influenza Antiviral Market Data.
5. Statista. (2022). Influenza antiviral drugs revenue statistics.